







KAMESWARAN R.1*, SHANMUGA SUNDARAM RAJAGOPAL2, KRISHNAVENI KANDASAMY1, KARTHIKEYAN 
KRISHNAN1 
1Faculty of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur 313024, Rajasthan, India, 2
Received: 10 Jul 2018 Revised and Accepted: 18 Aug 2018 
Department of 
Pharmacology, J. K. K. Nattraja College of Pharmacy, Kumarapalayam 638183, Tamil Nadu, India 
Email: kamesjohashwanth@gmail.com 
ABSTRACT 
Objective: The aim of this study was to assess the potential drug interactions (pDIs) among hospitalized patients in cardiac and neurology wards in 
3 tertiary care hospitals. 
Methods: A prospective, observational study was carried out for a period of 12 mo. A sample of 1330 patients was assessed for pDDIs using 
Micromedex®
Results: A total of 1330 patients were analyzed and it was found that 685 were cardiac and 645 were neurology patients. The study identified 524 
(76.49%) cardiac patients and 425 (65.89%) neurology patients, with potential drug-drug interactions (pDDIs) higher in male cardiac [298 
(56.87%)] and male neurology [235 (55.29%)] patients, compared to females. Incidences of pDDIs were found to be higher in the age group of 60-
70 y in cardiac [193 (36.83%)] and neurology [165 (38.84%)] patients and incidences of interactions based on duration of (4-6 d) hospital stays in 
cardiac were 380 (72.53%) and 275 (64.70%) in neurology patients respectively. Moreover, 51.90% cardiac patients and 57.41% neurology 
patients were found to be prescribed with more number of drugs in cardiac and neurology (7 drugs) patients, were found to have developed higher 
incidences of pDDIs. The most common drug interacting pair was between aspirin and clopidogrel combination, observed in 245 cardiac and 316 in 
neurology patients. Drug-food interactions (DFIs) were found with between atorvastatin-citrus fruits in cardiac and phenytoin-protein rich foods in 
neurology patients. The most common drug-disease interaction (D-DIs) was found to between isosorbide dinitrate–myocardial infarction in cardiac 
and carbamazepine-seizuresin neurology respectively. 
-2.7and drugs.com and www.dugs.com. 
Conclusion: It is recommended that physicians should be aware of the interactions among those drugs while prescribing, and careful monitoring is 
also required. 
Keywords: Cardiac, pDDIs, Neurology, Aspirin and clopidogrel, Carbamazepine-seizures 




Drug-drug interactions are defined as two or more drugs interacting 
in such a manner that the effectiveness or toxicity of one or more 
drugs is altered [1, 2]. Drug-drug interactions (DDIs) are an 
important subgroup of Adverse Drug Events (ADE) [3], which are 
highly prevalent in patients receiving multiple-drug treatment [4]. 
The majority of the interactions occur because, either prescriber’s 
do not consider them relevant [5, 6], or prescriber may be receiving 
less information in the DDIs area. Polypharmacy, geriatric and 
patients with co-morbidities are considered as one of the major risk 
factors in the precipitation of Drug-Drug interactions (DDIs) [5]. 
Neurological illnesses are one among the most common causes of 
hospitalization. It is estimated that DDIs account for approximately 
2.8% of hospital admission every year [6]. The issue of drug 
interactions is a global concern, a study of the US reported that 
30.3% patients aware at risk of DDIs [7]. A recent study in Iran has 
reported that in 35.5% of the patients in the neurology department 
encountered at least one pDDIs (Potential Drug-Drug Interactions) 
[8]. The burden of neurological disorders in India is estimated at 
over 30 million, which often warrant complex therapeutic regimen 
[9]. In India, a study identified 66% of DDIs in a medicinal 
department of a tertiary care hospital in Karnataka, India [10], while 
another study in Chandigarh reported that 8.3% prescriptions had 
multiple DDIs [11]. It was estimated that about 46.3% drug 
interactions were seen in neurological patients in a cross-sectional 
study conducted in Karnataka and majority of the DDIs were 
moderate in severity and required therapeutic monitoring [12]. An 
exhaustive literature search did not reveal as many published 
reports on DDIs in neurological disorders in Indian population or 
other countries, however similar studies in other hospital wards has 
been done.  
The present study was aimed to determine the prevalence and 
assessment of pDDIs in patients admitted to cardiology and 
neurology department and to identify pDDIs risk factors. In view of 
the above-mentioned statistics, we purposefully conducted this 
study in a tertiary care hospital in Erode as there are no studies 
targeted this region of the country. 
Diet and lifestyle can sometimes have a significant impact on 
drugs. These may occur out of accidental misuse or due to lack of 
knowledge about the active ingredients involved in the relevant 
substances. Interactions between food and drugs may 
inadvertently reduce or increase the drug effect. Major side 
effects of some diet (food) on drugs include alteration in the 
absorption of fatty, high protein and fiber diets. Sixteen cohort 
and case-control studies reported an elevated risk of 
hospitalization in patients who were exposed to pDDIs [13]. 
Studying the drug-drug interactions, drug-food interactions and 
drug-disease interactions are essential for the management of 
drug therapy. As per our knowledge, there are no studies were 
conducted in our study area. Hence we carried out a study to 
assess the prevalence of drug-drug interactions, drug-food 
interactions, and drug-disease interactions.  
MATERIALS AND METHODS 
The research was conducted in three tertiary care hospitals, the 
work was reviewed and approved by the Institute Ethics Committee 
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(Human Studies), ethics number is PP/2015/01 and hospital 
approved number is EMC/PhD/0130T15. Erode for a period of 12 
mo in the hospitalized cardiac and neurology patients. 1330 patients 
were taken in for the study, out of these; there were cardiac 685, 
neurology 645 patients. Exclusion criteria were outpatients and 
patients less than 18 y of age, medical disability, as well as the 
patients who are on Ayurveda, Siddha or other alternative systems 
of medicine. The consent form was obtained from the hospital 
authority and hospitalized patients. The data were collected from 
case sheets of hospitalized patients and direct patient interview 
from cardiac and neurology departments. Demographic information 
(age and sex), length of hospital stay, main diagnosis, number of 
drugs and details of comorbidities were obtained from the clinical 
records. pDDIs were detected using the Drug Interactions Checker 
within Micromedex®
RESULTS 
-2.7 and www.drugs com 
A total of 1330 patients were admitted in the department of cardiac and 
neurology during the study period. Among these, 685 were cardiac and 
645 were neurology patients. Out of 685 cardiac patients, 524 (76.49%) 
had found to be pDDIs. 856 pDDIs were found in 524 cardiac patients. 
795 pDDIs were found in 645 neurology patients. Out of which [298 
(56.87%)] cardiac male and [235(55.29%)] neurology male was found 
to be higher pDDIs, compared to females. Incidences of pDDIs were 
found to be higher in the age group of 60-70 y in cardiac [193(36.83%)] 
and neurology [165 (38.84%)] patients and incidences of interactions 
based on duration of (4-6 d) hospital stays in cardiac were 380 (72.53%) 
and 275 (64.70%) in neurology patients respectively. 51.90% patients 
and 57.41%, cardiac and neurology patients prescribed with more than 
7 drugs in cardiac and neurology patients were found to have developed 
higher incidences of pDDIs. 
 
Table 1: Demographic profile of cardiac and neurology patients 
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Fig. 1: Distribution of drug interactions in various departments 
 
Table 2: Types of diseases in each department 
Cardiology (n=524) Neurology (n=425) 
Type of diseases No. of. patients Type of diseases No. of. patients 
Myocardial Infarction 87 (16.60%) Stroke 187 (44.00%) 
Angina+Diabetes mellitus 111 (21.18%) Stroke+Alzheimer's disease 21 (04.94%) 
Hypertension 165 (31.48%) Stroke+Parkinson's disease 32 (07.52%) 
Ischaemic Heart Disease 46 (08.77%) Stroke+Epilepsy 43 (10.11%) 
Coronary Artery Disease 34 (06.48%) Epilepsy 117 (27.52%) 
Chronic Heart Failure 81 (15.45%) Parkinson's disease 25 (05.88%) 
On average, each patient had one or two coded diagnoses, in which hypertension was the most common condition165 (31.48%), followed by Angina 
with Diabetes mellitus 111(21.18%) in cardiac patients and Stroke 187 (44.00%), followed by Epilepsy 117 (27.52%) in neurology patients (table 2). 
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Table 3: Highest potential drug-drug interaction combinations in cardiology 
pDDIs combination Type Severity Frequency (n=856) Percentage (%) 
T. Asprin+T. Clopidogrel PD Major 245 28.62% 
T. Aspirin+T. Enalapril PD Moderate 69 8.06% 
T. Atorvastatin+T. Clopidogrel PK Moderate. 78 9.11% 
T. Aspirin+T. Atenolol PD Moderate 25 2.92% 
T. Clopidogrel+T. Amlodipine PK Moderate 80 9.34% 
T. Atenolol+T. Metformin PK Major 25 2.92% 
T. Spironolactone+T. Enalapril PD Moderate 18 2.10% 
T. Enalapril+T. Metformin Unknown Major. 15 1.75% 
T. Enalapril+T. Furosemide PD Moderate 12 1.40% 
T. Aspirin+T. Spironolactone PD Major 41 4.78% 
Note: PD= Pharmacodynamics, PK= Pharmacokinetics 
 
Table 5: Highest potential drug-drug interaction combinations in neurology 
pDDIs combination Type Severity Frequency (n=795) Percentage (%) 
T. Aspirin+T. Clopidogrel PD Major 316 39.74% 
T. Carbamazepine+T. Phenytoin PK Major 92 11.57% 
T. Aspirin+T. Metformin PD Major 70 8.80% 
T. Amlodipine+T. Clopidogrel PK Major 49 6.61% 
T. Atorvastatin+T. Clopidogrel PK Moderate 37 4.24% 
T. Clonazepam+T. Theophylline PD Moderate 25 3.14% 
T. Phenytoin+T. Clonazepam PK Moderate 78 9.81% 
T. Clobazam+T. Carbamazepine PK Minor 45 5.66% 
T. Amitriptyline+T. Fluoxetine PK+PD Major 42 5.28% 
T. Diazepam+T. Phenytoin Unknown Major 41 5.15% 
 
Table 7: Prevalence of pDDIs 
S. No. Type of prevalence Cardiology Neurology 
Severity of pDDIs Frequency (n=856) Frequency (n=795) 
1. Major 456 (53.27%)  302 (37.98%) 
2. Moderate 251 (29.33%) 341 (42.89%) 
3. Minor 149 (17.40%) 152 (19.11%) 
 
 
Fig. 2: Prevalence of pDDIs 
 
Table 8: Distribution of potential drug-food interactions in cardiology 




T. Atorvastatin with  citrus fruits Decreased first pass metabolism and increased bioavailability PK Moderate 144(31.50%) 
T. Enalapril with  Banana Hyperkalaemia Unknown Moderate 47(10.28%) 
T. Atenolol with orange juice Decrease the mean peak plasma concentration of atenolol; 
excretion of the drug into urine decreased 
PK Moderate 79(17.28%) 
T. Diazepam with  Tea/Coffee Antagonistic Effect. Caffeine generally antagonized the 
diazepam-induced ratings of sedation and impairment of 
psychomotor performance 
PD Minor 83(18.16%) 
T. Bisacodyl with Milk Increase the risk of stomach upset and nausea. Unknown Minor 91(19.91%) 
T. Paracetamol with Cabbage Decrease effectiveness of the drug. PK Moderate 38(8.31%) 
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Table 9: Distribution of potential drug-food interactions in neurology 
pDFIs Anticipated effects Type of DDI Severity Frequency (n=385) 
T. Phenytoin with Protein Rich Foods 
(Fish, Milk, Egg, Meat) 
Altered Phenytoin concentration PK Moderate 97 (25.19%) 
T. Carbamazepine with 
Black tea 
Decreased Carbamazepine bioavailability PK Moderate 65 (16.88%) 
T. Acetaminophen with 
Cabbage 
Decreased Acetaminophen Effectiveness PD Moderate 23 (5.97%) 
T. Diazepam with Tea/Coffee Reduced Sedative and Anxiolytic effect of 
Diazepam 
PD Minor 45 (11.68%) 
 
 
Fig. 3: Classification of types of pDDIs 
 
Table 10: Distribution of potential drug-disease interactions in cardiology 
pD-DIs Anticipated effects Severity Frequency (n=289) 
T. ISDN with MI Systemic hypotension and tachycardia Major 42(14.53%) 
Inj. Furosemide 
With DM 
(latent diabetes may become overt: insulin requirements in established diabetes may 
increase: stop furosemide before a glucose tolerance test) 
Moderate 56(19.37%) 
T. Atenolol with 
DM 
Inhibit catecholamine-mediated glycogenolysis, thereby potentiating insulin-induced 
hypoglycemia and delaying the recovery of normal blood glucose levels. 
Major 24(8.30%) 
T. Enalapril with 
CHF 





Unknown Mechanism Major 18(6.22%) 
Note: pD-DIs=Potential Drug-disease interactions, ISDN= Isosorbide dinitrate, MI= Myocardial Infarction, DM= Diabetes mellitus, CHF= Congestive 
heart failure, CAD= Coronary artery diseases. 
 
Table 11: Distribution of potential drug-disease interactions in neurology 
pD-DIs Anticipated effects Severity Frequency (n=215) 
T. Carbamazepine with Seizures Increased frequency of generalized convulsions Moderate 46 (21.39%) 
T. Atorvastatin with DM Increased HbA1C and Fasting blood sugar levels Moderate 45 (20.93%) 
T. Diazepam with seizures Increased frequency of seizure episodes Major 21 (9.76%) 
T. Telmisartan with DM Increased risk for new onset of Diabetes Major 16 (7.44%) 
T. Clopidogrel with 
Intracranial Haemorrhage 
Increased risk of Bleeding Major 15 (6.97%) 
Note: DM= Diabetes mellitus 
 
DISCUSSION 
DIs are a major area of concern these days for the effective 
management of patient illness. It may create a considerable health 
hazard to the patients when the risk-benefit ratio of combining 
interacting drugs is not accurately estimated. It has already been 
approximated that the effect of drug interactions can range from any 
minor morbidity to fatal consequences. The study of drug-drug, 
drug-food, and drug-disease interactions and of genetic factors 
affecting pharmacokinetics and pharmacodynamics is expected to 
improve drug safety and will enable individualized drug therapy. 
The present study identified a total of 1330 patients were admitted 
to the department of cardiology and neurology during the study 
period. Among these, 685 were cardiac and 645 were neurology 
patients. Out of 685 cardiac patients, 524 (76.49%) had found to be 
pDDIs. 856 pDDIs were found in 524 cardiac patients. Our study 
showed that cardiac male 298 (56.87%) patients, neurology 235 
(55.29%) patients had more interactions than female cardiac 226 
(43.13%), neurology 190 (44.71%), which are similar to the study 
has shown [14]. Another study has shown [15]. Also reports that 
male patients are higher cardiology (50.94%), neurology (54.73%), 
and a number of male patients, when compared to females in the 
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present study, may be the primary reason. Another reason possibly 
will be the greatest risk of cardiovascular, neurological disorders 
among male gender when compared to female and hence there is a 
need for multiple drugs which ultimately result in drug interactions. 
The study the majority of the Incidences of pDDIs were found to be 
higher in the age group of 60-70 y in cardiac [193 (36.83%)] and 
neurology [165 (38.84%)] patients. A study [16] has reported an age 
group of 59–69 y, whereas, a study [17, 34] has reported that the 
majority of patients ages were between 70-74 y. Older people are at 
high risk of developing an ADR due to pDDIs for several reasons. 
They are likely to have higher comorbidities and thus take several 
prescriptions and over the counter drugs. As people get older, the 
liver loses the ability to metabolize drugs. Also, older people are 
more than twice as susceptible to ADRs as younger people. As 
people age, the amount of water in the body decreases and the 
amount of fat tissue relative to water, increases. Also, as people age, 
the kidneys are less able to excrete drugs into the urine, and the liver 
is less able to metabolize many drugs. 
The study revealed that [380 (72.53%)] cardiac, [275 (64.70%)] 
neurology of patients, and reported that the number of days hospital 
stay was between 4-6 d (table 1). A study [18], which showed that 
the majority of the cases, the number of hospital stay were less than 
6 d. The likelihood of getting the multiple drugs increases with the 
increased length of hospital stay which in turn will increase the 
likelihood of pDDIs. 
In our study, 51.90% cases,per day more than 7 drugs were 
prescribed in the cardiology department (table 1). The study [19] 
has shown that 40.60% cases have been reported as the prescribing 
between 13 to 16 drugs.57.41% neurology department more than 7 
drugs were prescribed (table 1); a study [20] has shown, whereas 
62% cases are reported to prescribe more than 8 medications in the 
neurology department. Similar to another study [21] has reported 
the concurrent use of three or more drugs increases the risk of 
ADE’s by 9.8 times. More the medications that are prescribed, the 
more the possibility of irrational polypharmacy. A study [22] has 
determined the probability of potent cytochrome P450 (CYP 450) 
interactions in older hospitalized people taking more than five 
concurrent medicines. Potential drug-drug interactions are present 
in 80% of people taking more than 5 concurrent medicines. People 
taking 5 concurrent medicines have a 50% probability of at least one 
drug interaction, each additional medicine adds a 12% increase in 
the risk of drug interactions. 
The most common interacting pair in the cardiac department in the 
present study was found to be between aspirin and clopidogrel; 
which is a major pharmacodynamic interaction, with a frequency of 
245 (table 3). The similar study by [23] in which most common 
interacting pair was identified as aspirin–clopidogrel followed by 
clopidogrel–Fondaparinux. Another study [24] observed an 
increased risk of bleeding when aspirin combined with another 
thrombolytic agent. The most common interacting pair in the 
neurology department in the present study was found to be between 
Aspirin and Clopidogrel; which is a major pharmacodynamic 
interaction, with a frequency of 316 (table 5). This interacting pair 
increases the risk of bleeding; which is managed by monitoring 
blood counts. The similar study [25] has reported in which most 
common interacting pair was identified as aspirin–clopidogrel. 
Another study [8] which is quite different from this study identifies 
the most common interacting pair as clopidogrel-omeprazole. 
The prevalence of pDDIs in the cardiac department in our study was 
53.27% (table 7). A similar study was [26] showed an overall 77.5% 
pDDIs prevalence rate among randomly selected cardiac patients. A 
study [23] has reported to the department of cardiology showed that 
the prevalence rate of the bodice was 91.6% among the studied 
cardiac patients. The prevalence of pDDIs in the neurology 
department in our study was 42.89% (table 7). A similar study [27] 
in the department of Neurology showed that the prevalence rate of 
pDDIs was 71.6% among the patients. 
In our study, the prevalence of pDDIs was more in major severity in 
cardiology. Moderate severity in neurology (table 7). A similar study 
[28] has reported pDDIs of major severity in 13% patients and [26] 
has reported in 24.25% patients. Prevalence of pDDIs of moderate 
severity was 30.94%. Another study [24] has reported moderate 
severity in 60.3% of patients. This study contrasts the other studies 
which report moderate severity. These potential DDIs suggest that 
there is a need for modification or alteration of therapy such as 
dosage adjustment. In order to prevent these DDIs, health care 
providers should have adequate information about DDIs not only via 
drug information center, which can provide evidence-based 
information to health care professionals, but also through 
encouraging the empowerment of clinical pharmacists that can 
provide evidence-based approach to drugs and thereby prevent drug 
therapy problems of which DDIs is one. 
Out of 524 cardiac cases, there was 82 interacting pair identified 
during the study. Among 856 pDDIs, 256 (29.90%) were 
pharmacokinetic interactions, 456(53.27%) were pharmacodynamic 
interactions. 71(8.29%) showing both mechanisms and 73(8.54%) 
were the unknown mechanisms. Among 256 pharmacokinetic drug 
interactions, 39 (15.23%) were due to absorption, 41 (16.01%) were 
due to distribution, 141 (55.07%) were due to metabolism and 
35(13.67%) were due to excretion. Among 456pharmacodynamic 
interactions, 28 (6.14%) were synergistic, 115 (25.21%) were 
antagonistic, 294 (64.47%) were additive and 19 (4.18%) with both 
additive and antagonistic effects. A similar study [29] has reported, 
among 423 pDDIs, 50.83% were pharmacodynamic drug interactions, 
38.53% pharmacokinetic, and 10.64% showing both kinds of 
mechanisms. From the 163 pharmacokinetic pDDIs, 45.41% have 
altered the absorption, 28.99% have altered the metabolism, and 
25.60% have altered the excretion. Of the 215 pharmacodynamic 
pDDIs, 67.44% were synergistic, 30.70% antagonistic and 1.86% 
unknown in nature. The similar study [34] has reported, the majority 
being pharmacodynamic interaction is that these types of interactions 
derive from modification of the action of one drug at the target site by 
another drug, independent of a change in its concentration. This may 
result in an enhanced response (synergism), an attenuated response 
(antagonism) or an abnormal response. 
Out of 425 neurology cases, there was 72 interacting pair identified 
during the study. Among795 pDDIs, 396 (49.68%) were 
pharmacokinetic interactions, 289 (36.50%) were 
pharmacodynamic interactions. 69 (8.67%) showing both 
mechanisms and 41 (5.15%) were the unknown mechanisms. 
Among 396 pharmacokinetic drug interactions with the neurology 
department, 282 (71.21%) were due to metabolism. 289 
pharmacodynamic interactions, 158 (54.67%) were Additive which 
is in contrast with the study by [29], where 67.44% were 
synergistically followed by 30.7% antagonistic.  
Diet and lifestyle can sometimes have a significant impact on drugs. 
These may occur out of accidental misuse or due to lack of 
knowledge about the active ingredients involved in the relevant 
substances. Interactions between food and drugs may inadvertently 
reduce or increase the drug effect. Major side effects of some diet 
(food) on drugs include alteration in the absorption of fatty, high 
protein and fiber diets. 
According to this study, a total of 1330 patients were admitted to the 
department of cardiac and neurology during the study period. 
Among these, 685cardiac patients and 645 neurology patients. Out 
of 685 cardiac patients, 290 (42.33%) had found to be drug-food 
interactions. 457 pDFIs were found in 290 cardiac patients. Out of 
645 neurology patients, 235 (34.55%) had found to be pDFIs. 385 
pDFIs were found in 235 neurology patients. The Most of the cardiac 
cases had pDFIs between atorvastatin–citrus fruits interactions 
(table 6), with a frequency of 144, which may cause decreased first-
pass metabolism and increased bioavailability of atorvastatin that 
further results in muscle breakdown, liver damage, digestive 
problems, increased blood sugar and neurological side effects. The 
reason for these interactions is due to furanocoumarins. The 
interaction between citrus fruits and medications poses dangers 
only if a drug is taken orally because the interaction occurs in the 
digestive tract. The second most common interaction was banana 
interacting with the ACE inhibitors, with a frequency of 83, to cause 
hyperkalemia [30]. Bananas are high in potassium. Too much 
potassium can cause an irregular heartbeat, and heart palpitations. 
Kameswaran et al. 
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Out of 385 drug-food interactions with the neurology department, 
97 cases reported phenytoin with protein-rich foods (fish, milk, egg, 
meat) (table 7). Moderate, as the drug, must be taken on an empty 
stomach. This interaction results in altered phenytoin 
concentrations. A similar study by [31] conducted a study which 
reported that a simultaneous intake of green vegetables and heparin 
causes a decreased anticoagulant effect. The total number of drug-
food interactions and its prevalence is 230 and 48.42% respectively. 
According to this study, a total of 1330 patients were admitted to the 
department of cardiac and neurology during the study period and 
conducted direct patient interview, among these, 685cardiac patients 
and 645 neurology patients. Out of 685 cardiac patients, 175 (42.06%) 
had found to be potential drug-disease interactions. 289 pD-DIs were 
found in 175 cardiac patients. Out of 645 neurology patients, 148 
(35.57%) had found to be pD-DIs. 215 pD-DIs were found in 148 
neurology patients. The most common drug-disease interaction was 
found to be ISDN with MI (table 8). The interaction may result in 
systemic hypotension and tachycardia. It may also exacerbate 
myocardial ischaemia. The second common pD-DIs interaction was 
found to be furosemide-DM. This interaction may result in latent 
diabetes may become overt: insulin requirements in established diabetes 
may increase. So it is advisable to stop furosemide before a glucose 
tolerance test. The most common pD-DIs in neurology was found to be 
carbamazepine-seizures (table 9). The interaction may result in 
increased frequency of generalized convulsions. So it should be used 
with caution in patients with a mixed seizure disorder that includes 
atypical absence seizures. The second common pD-DIs was found to be 
atorvastatin-DM. This interaction may result in increased HbA1C and 
fasting blood sugar levels. So caution should be exercised when using 
these agents in diabetic patients and close monitoring is recommended. 
So it is advisable to stop atorvastatin before glucose test; a contradiction 
to our study by [32], which reported that the effects of furosemide may 
contribute to the decrease in glucose utilization. 
LIMITATION  
The study was carried out in a hypothetical way of approach to find 
the prevalence of drug interactions. The active possibilities of DIs 
respect to the time of drug administration, the half-life of drugs, 
elimination time were not assessed. The study also could not assess 
the outcomes of DIs in the selected hospitalized patients.  
CONCLUSION 
Our study concluded that the overall incidence of pDDIs was very high 
in the Department of Cardiology. It was found that the incidence of 
pDDIs was associated with older age, polypharmacy, increased lengths 
of hospital stay and increased number of prescribed drugs. DDIs are 
real with uncertain clinical implications. Therefore, our study 
highlights the DDIs, which is high among cardiac and neurology 
patients prescribed with aspirin drug with clopidogrel. Whereas in 
food-drug interactions in cardiac patients with atorvastatin drug with 
citrus fruits and neurology patients with phenytoin drug with protein-
rich foods and disease-drug interactions in cardiac patients with ISDN 
drugs with MI, neurology patients with carbamazepine–seizures in a 
tertiary care teaching hospital. It is recommended that physicians 
should be aware of the interactions among those drugs while 
prescribing, and careful monitoring is also required. 
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